Interleukin 1 enhances arterial thrombogenicity in vitro.
An in vitro model of platelet adhesion, the annular perfusion chamber, was utilized to test the effects of Interleukin 1 on vascular thrombogenicity for platelets. De-endothelialized, everted human umbilical arteries were placed in cell culture media with or without Interleukin 1. The arteries were later perfused with citrated human blood and then fixed. Platelet adhesion and aggregate formation on artery segments was quantified by blinded morphometric analysis. A monolayer of contact platelets was seen on control artery segments, but arteries exposed to 100 Units/ml Interleukin 1 for 2-20 hours had increased numbers and size of platelet aggregates. Ultrastructurally, intact endothelial cells were not present on any segment. Both prostacyclin and thromboxane were released by vascular cells in the artery segments, but the quantity and ratio of these eicosanoids was not altered by artery exposure to Interleukin 1. Arterial thrombogenicity is modulated by non-endothelial vascular cells in response to Interleukin 1, and this does not appear to be mediated by changes in vascular production of thromboxane or prostacyclin.
Schorer
A E
AE
Department of Medicine, Minneapolis VA Medical Center, MN.
White
J G
JG
D015121:6-Ketoprostaglandin F1 alpha / Q000096:biosynthesis; D001157:Arterial Occlusive Diseases / Q000139:chemically induced*; D006801:Humans; D066298:In Vitro Techniques; D007375:Interleukin-1 / Q000494:pharmacology*; D010477:Perfusion; D010974:Platelet Aggregation / Q000187:drug effects; D013927:Thrombosis / Q000139:chemically induced*; D013929:Thromboxane B2 / Q000096:biosynthesis; D014469:Umbilical Arteries / Q000187:drug effects / Q000378:metabolism
D007375:Interleukin-1; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha